(Total Views: 186)
Posted On: 10/03/2018 5:11:03 PM
Post# of 333
NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Provides Update on Progression of CBD Patents, Reacts to DEA’s Shifted Stance toward CBD
Biotechnology company Earth Science Tech Inc. (OTCQB: ETST) this morning issued an update on the progression of its cannabidiol patents, as well as its reaction to the U.S. Drug Enforcement Agency’s recent decision to remove certain CBD products from its Schedule 1 list of controlled substances. Per the update and as previously announced, ETST intends to launch two CBD-based nutraceutical formulas – a neuron protector and a breast protector – under a provisory patent. The company noted that the Quebec Agrifood Innovation Center is finishing the standardization of the formulas and, by the end of October, TransBiotech is expected to conduct in vitro testing for the formulas’ biological activities. “The results obtained from TransBiotech will help us understand the mechanism of action of CBD and will open the doors for the research needed to develop revolutionary CDB-based pharmaceutical drugs,” Nickolas Tabraue, president and CEO of ETST, stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company Earth Science Tech Inc. (OTCQB: ETST) this morning issued an update on the progression of its cannabidiol patents, as well as its reaction to the U.S. Drug Enforcement Agency’s recent decision to remove certain CBD products from its Schedule 1 list of controlled substances. Per the update and as previously announced, ETST intends to launch two CBD-based nutraceutical formulas – a neuron protector and a breast protector – under a provisory patent. The company noted that the Quebec Agrifood Innovation Center is finishing the standardization of the formulas and, by the end of October, TransBiotech is expected to conduct in vitro testing for the formulas’ biological activities. “The results obtained from TransBiotech will help us understand the mechanism of action of CBD and will open the doors for the research needed to develop revolutionary CDB-based pharmaceutical drugs,” Nickolas Tabraue, president and CEO of ETST, stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
